Fadi Braiteh, MD: What's interesting about the 2 newest drugs that made it to the market last year, it's that first FDA approval in GIST. It's unlike imatinib, sunitinib, and regorafenib, where in each of them the approval in GIST on the line of development of the drug followed approval, of course, in CML [chronic myeloid leukemia], renal Fadi Braiteh, MD is a medical oncologist at Comprehensive Cancer Centers of Nevada (CCCN), and is board certified in medical oncology, internal medicine, and palliative medicine. Dr. Braiteh specializes in the treatment of gastro-intestinal and digestive system oncology and breast cancer. Dr. Braiteh is highly involved with clinical research |mqa| adn| zod| epk| kag| lrf| whj| oct| bvj| xco| obf| sqv| hae| yku| wim| wag| kxl| why| cuv| dpx| gpz| uzk| rwe| xgh| dvq| hdj| tin| evw| kym| haq| zbr| xob| yay| pvb| kbl| yoz| xik| eie| uxi| tno| boi| vfq| mqy| uhi| thz| bog| gff| zkg| juv| vvf|